Patrick Hess

3.7k total citations
65 papers, 2.8k citations indexed

About

Patrick Hess is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Physiology. According to data from OpenAlex, Patrick Hess has authored 65 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 23 papers in Molecular Biology and 22 papers in Physiology. Recurrent topics in Patrick Hess's work include Nitric Oxide and Endothelin Effects (22 papers), Renin-Angiotensin System Studies (17 papers) and Receptor Mechanisms and Signaling (13 papers). Patrick Hess is often cited by papers focused on Nitric Oxide and Endothelin Effects (22 papers), Renin-Angiotensin System Studies (17 papers) and Receptor Mechanisms and Signaling (13 papers). Patrick Hess collaborates with scholars based in Switzerland, China and United States. Patrick Hess's co-authors include Martine Clozel, Changbin Qiu, Markus Rey, Jean‐Paul Clozel, Walter Fischli, Thomas Weller, Marc Iglarz, Oliver Nayler, Stephan Buchmann and Christoph A. Binkert and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Patrick Hess

64 papers receiving 2.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Hess 1.2k 782 693 620 425 65 2.8k
Alexander Treiber 568 0.5× 570 0.7× 309 0.4× 341 0.6× 281 0.7× 68 2.0k
Christophe Ribuot 465 0.4× 244 0.3× 797 1.2× 463 0.7× 97 0.2× 75 2.1k
Marc Pascal 779 0.7× 244 0.3× 142 0.2× 563 0.9× 51 0.1× 55 2.5k
R. Ouedraogo 285 0.2× 85 0.1× 391 0.6× 456 0.7× 82 0.2× 27 1.6k
Yoshiyuki Toya 1.1k 0.9× 189 0.2× 424 0.6× 1.4k 2.2× 26 0.1× 143 3.2k
René de Vries 881 0.8× 127 0.2× 517 0.7× 697 1.1× 27 0.1× 75 2.2k
Yoshiaki Masuda 1.0k 0.9× 401 0.5× 301 0.4× 880 1.4× 25 0.1× 98 2.2k
Valeria Paradies 560 0.5× 117 0.1× 426 0.6× 1.3k 2.1× 28 0.1× 69 2.6k
Lihong Diao 108 0.1× 291 0.4× 144 0.2× 1.0k 1.7× 103 0.2× 48 2.4k

Countries citing papers authored by Patrick Hess

Since Specialization
Citations

This map shows the geographic impact of Patrick Hess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Hess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Hess more than expected).

Fields of papers citing papers by Patrick Hess

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Hess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Hess. The network helps show where Patrick Hess may publish in the future.

Co-authorship network of co-authors of Patrick Hess

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Hess. A scholar is included among the top collaborators of Patrick Hess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Hess. Patrick Hess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Trensz, F., Markus Rey, Daniel S. Strasser, et al.. (2019). Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. Journal of Pharmacology and Experimental Therapeutics. 368(3). 462–473. 42 indexed citations
2.
Stritt, Manuel, Enrico Vezzali, Oliver Nayler, et al.. (2018). A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model. PLoS ONE. 13(3). e0193057–e0193057. 36 indexed citations
3.
Gatfield, John, Katalin Menyhart, Carmela Gnerre, et al.. (2017). Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential. Journal of Pharmacology and Experimental Therapeutics. 362(1). 186–199. 27 indexed citations
4.
Bolli, Martin H., Cyrille Lescop, Magdalena Birker, et al.. (2016). Novel S1P1 receptor agonists – Part 5: From amino-to alkoxy-pyridines. European Journal of Medicinal Chemistry. 115. 326–341. 12 indexed citations
5.
Morrison, Keith, et al.. (2015). REPEATED ORAL ADMINISTRATION OF THE SELECTIVE PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG DOES NOT CAUSE TACHYPHYLAXIS IN SPONTANEOUSLY HYPERTENSIVE RATS. Journal of the American College of Cardiology. 65(10). A1558–A1558. 7 indexed citations
6.
Bauer, Yasmina, John Tedrow, Simon de Bernard, et al.. (2014). A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 52(2). 217–231. 122 indexed citations
7.
Iglarz, Marc, et al.. (2014). Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sciences. 118(2). 333–339. 37 indexed citations
8.
Treiber, Alexander, Päivi Äänismaa, Ruben de Kanter, et al.. (2014). Macitentan Does Not Interfere with Hepatic Bile Salt Transport. Journal of Pharmacology and Experimental Therapeutics. 350(1). 130–143. 33 indexed citations
9.
Rey, Markus, Patrick Hess, Martine Clozel, et al.. (2013). Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P1 Receptor Modulator. PLoS ONE. 8(9). e74285–e74285. 14 indexed citations
10.
Piali, Luca, Sylvie Froidevaux, Patrick Hess, et al.. (2011). The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation. Journal of Pharmacology and Experimental Therapeutics. 337(2). 547–556. 89 indexed citations
11.
Corminboeuf, Olivier, Corinna Grisostomi, Sylvia Richard‐Bildstein, et al.. (2010). Design and optimization of new piperidines as renin inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(21). 6286–6290. 15 indexed citations
12.
Morrison, Keith, et al.. (2010). Selexipag: A Selective Prostacyclin Receptor Agonist that Does Not Affect Rat Gastric Function. Journal of Pharmacology and Experimental Therapeutics. 335(1). 249–255. 52 indexed citations
13.
Corminboeuf, Olivier, Corinna Grisostomi, Sylvia Richard‐Bildstein, et al.. (2010). Piperidine-based renin inhibitors: Upper chain optimization. Bioorganic & Medicinal Chemistry Letters. 20(21). 6291–6296. 16 indexed citations
14.
Iglarz, Marc, Christoph A. Binkert, Keith Morrison, et al.. (2008). Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics. 327(3). 736–745. 260 indexed citations
15.
Brisbare‐Roch, Catherine, Jasper Dingemanse, Ralf Koberstein, et al.. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine. 13(2). 150–155. 452 indexed citations
16.
Clozel, Martine, Christoph A. Binkert, Magdalena Birker, et al.. (2004). Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System. Journal of Pharmacology and Experimental Therapeutics. 311(1). 204–212. 108 indexed citations
17.
Bolli, Martin H., Christoph Boss, Martine Clozel, et al.. (2003). The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 13(5). 955–959. 9 indexed citations
18.
Ding, Shuangshuang, et al.. (2003). Chronic Endothelin Receptor Blockade Prevents Both Early Hyperfiltration and Late Overt Diabetic Nephropathy in the Rat. Journal of Cardiovascular Pharmacology. 42(1). 48–54. 51 indexed citations
19.
Clozel, Martine, Changbin Qiu, Chang-Shen Qiu, Patrick Hess, & Jean‐Paul Clozel. (2002). Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. Journal of the American College of Cardiology. 39(1). 142–147. 39 indexed citations
20.
Véniant, Murielle M., et al.. (1991). Hemodynamic Profile of Ro 40–5967 in Conscious Rats. Journal of Cardiovascular Pharmacology. 18. S55–S58. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Treiber Breakdown of academic impact, for papers by Christophe Ribuot Breakdown of academic impact, for papers by Marc Pascal Breakdown of academic impact, for papers by R. Ouedraogo Breakdown of academic impact, for papers by Yoshiyuki Toya Breakdown of academic impact, for papers by René de Vries Breakdown of academic impact, for papers by Yoshiaki Masuda Breakdown of academic impact, for papers by Valeria Paradies Breakdown of academic impact, for papers by Lihong Diao
Rankless by CCL
2026